ITRI wins 1 gold, 3 silvers at 2024 Edison Awards

2024-04-24

The winners are out for this year’s Edison Awards, which are known as the "Oscars of Innovation." The Industrial Technology Research Institute, or ITRI, claimed its highest number of awards yet: one gold and three silvers. It won gold for its pioneering eye drop therapy for glaucoma. ITRI said the awards are a testament to Taiwan’s strengths in biomedical, textile, and display technologies.

It’s an eye drop that effectively reduces eye pressure. This first-in-Taiwan technology, known as the Novel Dual-Targeted Therapy for Glaucoma, is shown to be three times more effective than existing medications on the global market. It also comes with fewer side effects. Already patented in Europe and the U.S., the therapy earned a gold medal at the 2024 Edison Awards, a first for any ophthalmic innovation from Taiwan.

Eric Chuang
Director of ITRI’s biotech lab
This award is proof of Taiwan’s research capabilities in developing new medications. We hope to break into a new ophthalmic drug market and compete at an international level.

Another award-winning technology is the Key Functional Cell Identity. Designed to support allogeneic cell therapy, it is a precise and standardized screening platform that quickly filters out unsuitable therapeutic cells. This technology can be applied to treat more than 40 medical conditions, including myocardial infarction and diabetes. It won a silver at this year’s Edison Awards.

Edwin Liu
ITRI president
Being recognized by the Edison Awards is no small feat. It requires not just innovative research and development, but most importantly, the ability to reach the commercial market.

Frank Bonafilia
Edison Awards executive director
You’re like an innovation factory. And you take not just the product that you’re looking at, but you’re looking at the entire process and how it fits within the supply chain, how it’s making people’s lives better. We couldn’t be happier for your attendance this year as well.

This is the eighth consecutive year that ITRI was honored at the Edison Awards. This year, the awards received nearly 400 submissions from around the world. ITRI won a gold and three silvers, its highest number of medals yet. The accolades testify to Taiwan’s strengths in biomedical, textile, and display technologies.

For more Taiwan news, tune in:
Sun to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53

"愛迪生獎"勇奪1金3銀工研院獲獎數創8年新高

2024-04-24

有"創新界奧斯卡獎"之稱的愛迪生獎，公布今年度獲獎名單，工研院連續8年獲獎，這次更勇奪1金3銀，獲獎數創新高，尤其雙標靶青光眼藥物，是台灣在眼科學創新新藥，拿下的首面金牌。工研院表示，透過獲獎關鍵技術，也讓台灣生醫、紡織、顯示器科技研發實力，持續在國際發光，並落實產業合作。

只要點眼藥水，就能有效降眼壓，國內首度自主研發成功的"雙標靶青光眼藥物"，不僅成效優於國際大廠近3倍，也能減少副作用，目前已在歐美取得專利，更一舉拿下有"創新界奧斯卡獎"之稱的愛迪生獎金牌獎，是台灣在眼科學創新新藥的首面金牌。

[[工研院生醫所所長莊曜宇]]
“這次也透過技術的得獎，證明我們在新的藥物上面，台灣有自主研發的能力，我們希望能夠進到眼科藥物的新藍海市場，可以跟國際做競爭。”

另一個受到肯定的"細胞功能之鑰"技術，針對異體細胞治療，建立精準化與標準化的篩選機制，能夠快速過濾品質較差的細胞，適用心肌梗塞治療和糖尿病傷口修復，同樣在今年度的愛迪生獎中，摘下銀牌獎。

[[工研院院長劉文雄]]
“得到愛迪生獎是一件不簡單的事情，它不但要有創新的一些研發的成果，最重要能夠走到市場。”

[[愛迪生獎執行總監法蘭克．波納費里亞]]
“工研院不間斷的創新研發，尤其研發過程中，不僅考量技術，是否符合市場供應鏈需求，也在意能否為全人類謀福利，我們很高興能夠看到今年工研院再度獲獎。”

工研院連續8年獲獎，這次在全球近400多項創新科技產品中，更勇奪1金3銀，以合計4面的獎牌數再創新高。各項獲獎關鍵技術，也讓台灣在生醫、紡織、顯示器科研實力，在國際發光。

更多新聞內容，請鎖定：
民視台灣台（152頻道）週日至週五晚上9:30
民視新聞台（53頻道）週二至週六凌晨1:00